Patents by Inventor Daniel Guay

Daniel Guay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkyne-aryl phosphodiesterase-4 inhibitors
    Publication number: 20030114478
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: August 23, 2002
    Publication date: June 19, 2003
    Inventors: Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen
  • 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors
    Publication number: 20030096829
    Abstract: Compounds represented by Formula (I): 1
    Type: Application
    Filed: May 24, 2002
    Publication date: May 22, 2003
    Inventors: Chun Li, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen, Yves Girard, Daniel Guay
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020173661
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 20, 2002
    Publication date: November 21, 2002
    Applicant: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Method for rapidly carrying out hydrogenation of a hydrogen storage material
    Publication number: 20020141939
    Abstract: Disclosed is a method for rapidly carrying out a hydrogenation of a material capable of absorbing hydrogen. It was discovered that when a powder of a material capable of absorbing hydrogen is ground under a hydrogen pressure, not at room temperature but at a higher temperature (about 300° C. in the case of magnesium) and in the presence of a hydrogenation activator such as graphite and optionally a catalyst, it is possible to transform completely the powder of this material into a hydride. Such a transformation is achieved in a period of time less than 1 hour whereas the known methods call for periods of time as much as 10 times longer. This is an unexpected result which gives rise to a considerable reduction in the cost of manufacture of an hydride, particularly MgH2.
    Type: Application
    Filed: April 2, 2002
    Publication date: October 3, 2002
    Applicant: HYDRO-QUEBEC
    Inventors: Robert Schulz, Salim Bouaricha, Jacques Huot, Daniel Guay
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6399636
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 4, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Publication number: 20020013347
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pylidyl moiety are PDE4 inhibitors.
    Type: Application
    Filed: March 16, 2001
    Publication date: January 31, 2002
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
    Patent number: 6329421
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: December 11, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Petpiboon Prasit, Daniel Guay, Zhaoyin Wang, Serge Leger, Michel Therien
  • Heterosubstituted pyridine derivatives as PDE4 inhibitors
    Patent number: 6200993
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3′,5′-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE 4). or a pharmaceutically acceptable salt or hydrate thereof. The invention also encompasses pharmaceutical compositions and methods for treatment.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: March 13, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Bernard Cote, Richard Friesen, Richard Frenette, Mario Girard, Yves Girard, Cedrickx Godbout, Daniel Guay, Pierre Hamel, Marc Blouin, Yves Ducharme, Sylvie Prescott
  • 5-Methanesulfonamido-3H-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
    Patent number: 5968958
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: October 19, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Chun-Sing Li, Nathalie Ouimet
  • Leached nanocrystalline materials process for manufacture of the same, and use thereof in the energetic field
    Patent number: 5872074
    Abstract: Leached nanocrystalline materials having a high specific surface are particularly useful for storing hydrogen or as catalysts or electrocatalysts in the manufacture electrodes, especially for fuel cells. Such materials can be manufactured by preparing a nanocrystalline material consisting of a metastable composite or alloy of at least two different chemical elements. To be nanocrystalline, this material must have a crystalline structure with the grain size lower than 100 nm. Then, the so prepared nanocrystalline material can be subjected to a leaching treatment in order to eliminate partially or totally one of the elements of the composite or alloy. This leaching results in nanocrystalline materials having a porous structure and, thereby, the requested high specific surface.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: February 16, 1999
    Assignee: Hydro-Quebec
    Inventors: Robert Schulz, Guy Lalande, Jacques Huot, Marie-Chantal Denis, Guoxian Liang, Andre Van Neste, Daniel Guay, Jean-Pol Dodelet
  • Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5856322
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: February 8, 1996
    Date of Patent: January 5, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Serge Leger, Patrick Roy, Marc Labelle, Yi Bin Xiang, Daniel Guay
  • Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
    Patent number: 5817700
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: October 6, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Dube, Rejean Fortin, Richard Frenette, Richard Friesen, Daniel Guay, Sylvie Prescott
  • Diphenyl stilbenes as prodrugs to COX-2 inhibitors
    Patent number: 5733909
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: March 31, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cameron Black, Mario Girard, Daniel Guay, Zhaoyin Wang
  • Diphenyl pyridyl ethane derivatives as PDE IV inhibitors
    Patent number: 5710160
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Yves Girard, Yves Ducharme
  • Tri-aryl ethane derivatives as PDE IV inhibitors
    Patent number: 5710170
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Yves Girard, Yves Ducharme, Marc Blouin, Pierre Hamel, Mario Girard
  • N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
    Patent number: 5639780
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 17, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk Kun Lau, Cameron Black, Daniel Guay, Jacques-Yves Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
    Patent number: 5604253
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: February 18, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk K. Lau, Cameron Black, Daniel Guay, Jacques Y. Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
    Patent number: 5604260
    Abstract: The Compound of Formula I and pharmaceutically acceptable salts thereof in the treatment of cyclooxygenase-2 mediated diseases are disclosed.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: February 18, 1997
    Assignee: Merck Frosst Canada Inc.
    Inventors: Daniel Guay, Chun-Sing Li
  • Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5565473
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: October 15, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Serge Leger, Marc Labelle, Patrick Roy, Yi B. Xiang, Daniel Guay
  • 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
    Patent number: RE38103
    Abstract: The Compound of Formula I and pharmaceutically acceptable sales thereof in the treatment of cyclooxygenase-2 mediated diseases are disclosed.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: April 29, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Guay, Chun-Sing Li